{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:23:01Z","timestamp":1784067781186,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":129,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2024.04.015","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:23:11Z","timestamp":1715739791000},"page":"871-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the Risk of Poor Outcomes Among Hepatitis C\u2013Infected, Cured, and Never-Infected Controls"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-3455","authenticated-orcid":false,"given":"Varun","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreepriya","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk I.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna B.","family":"Ready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Schmittdiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2024.04.015_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastha.2024.04.015_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.04.015_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A\u00a0sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.04.015_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21 Suppl 1","author":"Razavi","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2024.04.015_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","article-title":"A\u00a0review of the treatment of chronic hepatitis C virus infection in cirrhosis","volume":"32","author":"Vezali","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.gastha.2024.04.015_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials","volume":"9","author":"Pecoraro","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A\u00a0risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastha.2024.04.015_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.04.015_bib10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib11","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","article-title":"Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response","volume":"105","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2024.04.015_bib12","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.04.015_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.04.015_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastha.2024.04.015_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.gastha.2024.04.015_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.04.015_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12884-016-1150-2","article-title":"The Kaiser Permanente Northern California research program on genes, environment, and health (RPGEH) pregnancy cohort: study design, methodology and baseline characteristics","volume":"16","author":"Hedderson","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.gastha.2024.04.015_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229218","article-title":"Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data","volume":"15","author":"Philip","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2024.04.015_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A\u00a0prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A\u00a0global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastha.2024.04.015_bib22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4093\/dmj.2019.0188","article-title":"Corrigenda: table correction. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis","volume":"43","author":"Lee","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.gastha.2024.04.015_bib24","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.cgh.2020.01.020","article-title":"Dallas steatosis index identifies patients with nonalcoholic fatty liver disease","volume":"18","author":"McHenry","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/MEG.0b013e32831cf2b3","article-title":"Nonischemic cardiomyopathy related to pegylated interferon and ribavirin","volume":"21","author":"Choy-Shan","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00042737-200603000-00010","article-title":"Fatal cardiomyopathy associated with pegylated interferon\/ribavirin in a patient with chronic hepatitis C","volume":"18","author":"Condat","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2024.04.015_bib28","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.04.015_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.04.015_bib30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2036.2004.01963.x","article-title":"Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C","volume":"19","author":"Lin","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2024.04.015_bib31","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T07:57:39Z","timestamp":1725091059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572324000657"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.04.015","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the Risk of Poor Outcomes Among Hepatitis C\u2013Infected, Cured, and Never-Infected Controls","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}